Welcome to our dedicated page for Phio Pharmaceuticals SEC filings (Ticker: PHIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Phio Pharmaceuticals Corp. filings document material events for a clinical-stage siRNA biopharmaceutical company developing INTASYL® gene-silencing therapeutics in immuno-oncology. Recent 8-K disclosures report quarterly and year-end financial results, PH-762 clinical and safety updates, tumor-response data, and development activities for skin cancer indications including cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
The company's regulatory record also covers material agreements and capital-structure matters, including a cGMP drug-product manufacturing services agreement for PH-762 clinical supply and an at-the-market common-stock offering under a shelf registration statement. Governance disclosures include executive employment-agreement amendments and related compensatory arrangements.
David H. Deming, a director of Phio Pharmaceuticals Corp. (PHIO), reported an acquisition on 09/11/2025 of 14,000 shares of common stock through restricted stock units (RSUs) with a reported price of $0. The filing states these shares represent units that will vest on the first annual anniversary of the grant and that the 14,000 shares reported include common stock underlying unvested RSUs.
The Form 4 was signed by attorney-in-fact Lisa C. Carson on 09/15/2025. The transaction increases the director’s beneficial ownership by the 14,000 shares subject to future vesting; no cash purchase price was reported in the filing.
Phio Pharmaceuticals (PHIO) director Curtis Lockshin reported an insider grant and updated holdings on Form 4. On 09/11/2025 he was granted 16,200 shares (reported as shares underlying a restricted stock unit) that will vest on the first annual anniversary of the grant; the grant was recorded at a $0 price. After the reported transaction, the filing shows Mr. Lockshin beneficially owns 18,555 shares, which includes shares underlying unvested restricted stock units. The filing notes the reported totals were adjusted for prior reverse stock splits and the Form 4 was signed on 09/15/2025 by an attorney-in-fact.
Phio Pharmaceuticals insider Jonathan E. Freeman reported acquisition of 14,700 shares of common stock on 09/11/2025 through restricted stock units that will vest on the first annual anniversary of the grant. Following the reported transaction Freeman beneficially owns 16,055 shares, a figure that includes other unvested restricted stock units. The filing states the reported amounts were adjusted to reflect prior reverse stock splits. The form was signed by an attorney-in-fact on behalf of the reporting person.
Robert L. Ferrara, a director of Phio Pharmaceuticals Corp. (PHIO), reported acquisition of 23,000 shares of common stock represented by restricted stock units on 09/11/2025. The RSUs vest on the first annual anniversary of the grant and the reported beneficial ownership following the transaction is 38,666 shares, which includes shares underlying unvested RSUs. The filing notes the reported share totals were adjusted for prior reverse stock splits. The disclosure was submitted on a Form 4 by a single reporting person and includes a power of attorney exhibit.
Phio Pharmaceuticals (PHIO) reporting person Lisa C. Carson, who is listed as a director and VP, Finance and Administration, reported a non-derivative acquisition on 09/11/2025. The filing shows 47,000 shares of common stock were acquired at $0, representing shares underlying a restricted stock unit grant. The filing states those shares "will vest on the first annual anniversary of the grant," and that the 47,000 shares reported include common stock underlying unvested restricted stock units. The form is signed 09/15/2025.
Phio Pharmaceuticals Corp. director Patricia A. Bradford reported a change in beneficial ownership related to restricted stock units. The filing shows an acquisition of 18,800 shares of common stock issued to satisfy restricted stock units that will vest on the first annual anniversary of the grant. Following the reported transaction, Ms. Bradford beneficially owns 27,151 shares, a total that the filing indicates includes shares underlying unvested restricted stock units. The reported share counts have been adjusted to reflect prior reverse stock splits. The transaction was reported as an acquisition at $0 per share, consistent with issuance upon vesting of RSUs.
Robert J. Bitterman, Chairman, President and CEO of Phio Pharmaceuticals Corp. (PHIO), reported equity transactions on a Form 4 filed for activity dated 09/11/2025. The filing shows 4,111 shares were withheld by the issuer to satisfy tax withholding related to vested restricted stock units; no shares were sold.
The reporting person was also granted 250,000 restricted stock units on that date that vest on the first annual anniversary of the grant. After these transactions the filing reports 271,421 shares of common stock beneficially owned by Mr. Bitterman. The Form 4 was signed by an attorney-in-fact on 09/15/2025.
Phio Pharmaceuticals Corp. filed a Form S-8 to register 1,005,555 additional shares of its common stock, par value $0.0001, for issuance under the Phio Pharmaceuticals Corp. amended and restated 2020 Long Term Incentive Plan. This filing expands the pool of shares available for equity-based awards such as stock options or restricted stock units to employees, directors, and other eligible participants under the 2020 Plan.
The company uses General Instruction E to Form S-8, incorporating by reference its prior S-8 registrations for the same plan and its ongoing Exchange Act reports, so new disclosures here are limited mainly to the additional registered shares and updated exhibits.
Phio Pharmaceuticals Corp. reported that it will present at the H.C. Wainwright 27th Annual Global Investment Conference, which is scheduled for September 8-10, 2025. The company also noted that patients are now being treated in the 5th cohort of its ongoing Phase 1b clinical trial for skin cancer, indicating continued progression of this early-stage study.
Phio Pharmaceuticals Corp. (PHIO) reported interim financials showing continued operating losses and active financing and warrant activity. The company recorded an operating loss of $2,309 and a net loss of $2,166 for the most recent quarter presented, compared with operating loss of $1,914 and net loss of $1,846 in the prior period. Cash flows show a net increase in cash of $5,393 for the period and modest investing outflows.
The filing discloses multiple financings and warrant issuances: net proceeds of approximately $2.646 million from a July 2024 financing, and subsequent registered direct and private placements in January 2025 generating approximately $2.9M, $2.2M, $1.6M and other raises. The company completed a 1-for-9 reverse stock split and recorded significant non-cash equity issuance costs (about $2.4M for warrant fair value and ~$0.2M placement agent warrants). Clinical and collaboration expenses include $4,000,000 incurred for a Phase 1 trial of PH-762. The report lists customary risk factors, reliance on third parties, and material uncertainty around future capital needs.